---
title: Personalized stimulation to improve walking
nct_id: NCT06350617
phase: NA
status: RECRUITING
sponsor: Samsung Medical Center
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06350617"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06350617"
last_fetched: "2026-05-10T14:05:46.816Z"
source: "Parkinson's Pathways (curated)"
---
# Personalized stimulation to improve walking

**Goal (in five words):** Personalized stimulation to improve walking

**Official Title:** Safety and Efficacy of Personalized Repetitive Transcranial Magnetic Stimulation Protocol Based on Functional Reserve to Enhance Ambulatory Function in Patients With Parkinson Disease

**Trial ID:** [NCT06350617](https://clinicaltrials.gov/study/NCT06350617)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Samsung Medical Center
- **Target Enrollment:** 60 participants
- **Start Date:** 2024-02-20
- **Completion Date:** 2026-09-30
- **Conditions:** Parkinson's Disease and Parkinsonism
- **Interventions:** High-Frequency, ipsilateral M1, High-Frequency, bilateral M1, High-Frequency, Lt. DLPFC, High-Frequency, bilateral M1
- **Intervention Types:** DEVICE

## Summary For Families

The goal is to help people with Parkinson's walk better by boosting the brain networks that support gait and balance. The approach uses personalized, high-frequency repetitive transcranial magnetic stimulation, targeting the motor cortex (one side or both) and sometimes the left dorsolateral prefrontal cortex, with the protocol tuned to each person’s functional reserve so the most responsive brain areas get stronger magnetic pulses; the pulses increase excitability in those circuits, they are noninvasive, and they do not replace levodopa but may make motor circuits more responsive to medications. The trial is looking for adults aged 50 and up with Parkinson’s (UK Brain Bank criteria) in Hoehn and Yahr stages 2 to 4 who can walk on flat ground without a gait aid. People with epilepsy or metal in the head, significant cognitive impairment by MoCA thresholds, other major neurological or psychiatric disorders, severe on-off swings or dyskinesia, MRI contraindications, or pregnancy are excluded.

## Eligibility

- **Minimum age:** 50 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

1. patients with Parkinson's disease, diagnosed by the United Kingdom (UK) Parkinson's Disease Society Brain Bank Diagnostic Criteria,
2. Modified Hoehn and Yahr (H\&Y) scale, stage 2\~4,
3. patients who can walk on flat surfaces without the need for a gait aid,
4. aged ≥50 years old,
5. patients willing to sign the informed consent.

Exclusion Criteria:

1. those with contraindications to rTMS, such as epilepsy, implanted metal objects in the head, or a history of craniotomy,
2. those with cognitive impairment, confirmed through the Montreal Cognitive Assessment (MoCA) test as follows: \< 7 points: Illiterate \< 13 points: Education duration 0.5-3 years \< 16 points: Education duration 4-6 years \< 19 points: Education duration 7-9 years \< 20 points: Education duration 10 years or more
3. those with coexisting neurological conditions, such as spinal cord injury or Stroke,
4. those with major psychiatric disorders, such as major depression, schizophrenia, or dementia,
5. those with severe on-off phenomena or severe dyskinesia, deemed by the investigators to render participation in the study inappropriate.
6. those having contraindications to conduct an MRI study,
7. those who are pregnant or lactating,
8. patients who have refused to participate in this study.
```

## Locations (1)

- Samsung Medical Center, Seoul, South Korea _(37.5660, 126.9784)_
  - Won Hyuk Chang, PhD — (CONTACT) — +82-2-3410-6068 — wh.chang@samsung.com

## Central Contacts

- Won Hyuk Chang, PhD — (CONTACT) — +82-2-3410-6068 — wh.chang@samsung.com
- Ho Seok Lee, PhD — (CONTACT) — +82-2-3410-2810 — hoseok89.lee@samsung.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT06350617*  
*HTML version: https://parkinsonspathways.com/trial/NCT06350617*  
*Source data: https://clinicaltrials.gov/study/NCT06350617*